BMN 190

BIOLOGICAL2 trials

Sponsors

BioMarin Pharmaceutical

Conditions

Batten DiseaseCLN2 DiseaseCLN2 DisorderJansky-Bielschowsky DiseaseLate-Infantile Neuronal Ceroid Lipofuscinosis Type 2

Phase 1

A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease

CompletedNCT01907087

BioMarin PharmaceuticalBatten Disease, CLN2 Disease, Jansky-Bielschowsky Disease +1

Start: 2013-09-30End: 2015-11-30Updated: 2019-03-08

An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease

CompletedNCT02485899

BioMarin PharmaceuticalBatten Disease, CLN2 Disease, CLN2 Disorder +2

Start: 2015-02-28End: 2020-12-10Updated: 2022-08-24

Related Papers

Exploring concurrent validity of the CLN2 Clinical Rating Scale: Comparison to PedsQL using cerliponase alfa clinical trial data

PLoS ONE2024-05-222 citations

Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study.

2024-01-0127 citations

Therapeutic potential of lysosomal cathepsins for neurodegenerative diseases

Neural Regeneration Research2022-12-111 citations

Natural History Studies in NCL and Their Expanding Role in Drug Development: Experiences From CLN2 Disease and Relevance for Clinical Trials.

2022-02-0818 citations

Investigating health-related quality of life in rare diseases: a case study in utility value determination for patients with CLN2 disease (neuronal ceroid lipofuscinosis type 2).

2021-05-1211 citations

Persistent Treatment Effect of Cerliponase Alfa in Children with CLN2 Disease: A 3 Year Update from an Ongoing Multicenter Extension Study

Neuropediatrics2019-09-018 citations

FV 1183. Long-Term Safety and Efficacy of Intraventricular Enzyme Replacement Therapy in CLN2 Disease: 2-Year Results from an Ongoing Multicenter Extension Study

Neuropediatrics2018-10-01

Study of Intraventricular Cerliponase Alfa for CLN2 Disease

New England Journal of Medicine2018-04-24456 citations